Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of the Cobas® Liat CT/NG/MG Test Versus Current Standard Practice for Managing Participants at Increased Risk of Sexually Transmitted Infections
NCT06369220 · View on ClinicalTrials.gov ↗
Study Summary
This study is designed to assess the comparative clinical utility of the point of care cobas® liat CT/NG/MG to current standard practices in the diagnosis and treatment of urogenital infections with Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Mycoplasma genitalium (MG).
Conditions Studied
Interventions
- DIAGNOSTIC_TEST cobas® liat CT/NG/MG nucleic acid test
- OTHER Standard of Care (SOC): Clinician's Standard Practice
Study Locations (4)
New Jersey
- Planned Parenthood of Northern, Central, and Southern New Jersey, Inc. — Hamilton Square
- Planned Parenthood of Northern, Central and Southern New Jersey — Perth Amboy
California
- San Francisco City Clinic — San Francisco
Texas
- Baylor Scott & White Health - Kileen — Killeen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 344 participants |
| Start Date | 2024-07-29 |
| Est. Completion | 2025-05-28 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06369220
The ClinicalTrials.gov registry entry for NCT06369220 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 344 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 758 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Neisseria Gonorrhoeae Infection appearing as the primary indexed condition, and to 2 interventions — of which cobas® liat CT/NG/MG nucleic acid test is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06369220 reports 4 study locations spanning 3 distinct geographic areas — top geographies include New Jersey, California, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06369220 about?
NCT06369220 is a clinical study titled "A Study of the Cobas® Liat CT/NG/MG Test Versus Current Standard Practice for Managing Participants at Increased Risk of Sexually Transmitted Infections". This study is designed to assess the comparative clinical utility of the point of care cobas® liat CT/NG/MG to current standard practices in the diagnosis and treatment of urogenital infections with Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Mycoplasma genitalium (MG).
What is the current status of trial NCT06369220?
This trial is currently completed. It is a NA study. The enrollment target is 344 participants. The study started on 2024-07-29. Estimated completion is 2025-05-28.
What conditions does trial NCT06369220 study?
This clinical trial studies the following conditions: Neisseria Gonorrhoeae Infection, Chlamydia Trachomatis Infection, Mycoplasma Genitalium Infection. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06369220?
The interventions under investigation include: cobas® liat CT/NG/MG nucleic acid test (DIAGNOSTIC_TEST), Standard of Care (SOC): Clinician's Standard Practice (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06369220?
This trial is sponsored by Hoffmann-La Roche, which has 758 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06369220 being conducted?
This trial has 4 study locations across California, New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.